BioCryst Pharmaceuticals Stock News

The biotech's immediate future doesn't look profitable.

The biotech''s immediate future doesn''t look profitable.

BCRX earnings call for the period ending December 31, 2021.

BCRX earnings call for the period ending December 31, 2021.

The biotech's immediate future doesn't look profitable.

BioCryst (BCRX) delivered earnings and revenue surprises of -29.03% and 2.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Imilian/iStock via Getty Images The commercial-stage biotech company BioCryst Pharmaceuticals (NASDAQ:BCRX) is trading ~7% lower in the pre-market on Wednesday after the companys Q4 2021

BioCryst Pharmaceuticals (NASDAQ: BCRX ) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings BioCryst Pharmaceuticals missed estimated earnings by 33.33%, reporting an EPS of $-0.4 versus Full story available on Benzinga.com

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2021 Results - Earnings Call Transcript

BioCryst Pharmaceuticals press release (BCRX): Q4 Non-GAAP EPS of -$0.40 misses by $0.11.Revenue of $47.2M (+1080.0% Y/Y) misses by $3.28M.ORLADEYO net revenue in the fourth quarter

BioCryst (BCRX) delivered earnings and revenue surprises of -29.03% and 2.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

By StoryTrading BioCrysts (NASDAQ: BCRX ) stock price hit 15-year highs since our article was published on Benzinga earlier this month, but with the oral prophylactic treatment providers 2021 financial results due out this Wednesday , some traders may be wondering whether its time to take some money off the table. A flurry of positive news and steadily rising sentiment could already be baked into the value of BCRX since StoryTrading contributor Zak Keller provided an update to our community. Technically, BCRX is up 59.5 percent in the last three months, countering iShares Biotechnology ETF (IBB), which fell 18.6 percent during the same time period. BCRX is also up more than 370 percent since the stock was presented to StoryTrading as a VIP Pick in Full story available on Benzinga.com

BioCryst Pharmaceuticals (NASDAQ:BCRX) is scheduled to announce Q4 earnings results on Wednesday, February 23rd, before market open.The consensus EPS Estimate is -$0.29 (+14.7% Y/Y) and

RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) today announced the enrollment of the first patient in the RENEW proof-of-concept basket study with its oral Factor D inhibitor, BCX9930, in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN). RENEW is an open-label, multicenter, proof-of-concept study designed to evaluate the safety, tolerability and therapeutic potential of BCX9930 (500 mg bid) administered for 24 weeks in approximately 42 adult patients (14 patients in each disease) with either C3G, IgAN or PMN. All patients will be enrolled into one of three parallel study cohorts, based on confirmation of diagnosis and disease activity in a recent kidney biopsy, and will receive BCX9930 for the 24-week treatment period. The primary endpoint of RENEW is percent change from baseline in 24-hour urine protein-to-creatinine ratio (uPCR), as assessed at week 24. For more information about RENEW, visit ClinicalTrials.gov and search NCT number NCT05162066. "There are currently no targeted treatments available for patients living with these rare renal diseases, which underscores the importance of the RENEW study," said Dr.